ADNP: A Literature Course on What Published Studies Report

This page is a structured reading course. It summarises what a set of peer-reviewed papers reported about ADNP — the gene, the protein it encodes, and the clinical syndrome associated with mutations in it. This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision. Nothing here is an instruction, a protocol, or a claim of benefit.

Module 1: What ADNP Is and How It Has Been Studied

Definition and class

ADNP stands for activity-dependent neuroprotective protein. It is a large, nuclear, zinc-finger and homeobox-containing protein encoded by a single human gene, and it is generally classified in the literature as a transcription-regulating and chromatin-associated protein rather than as a therapeutic peptide. Researchers have studied the full-length protein, its gene, and a short ADNP-derived peptide fragment referred to as NAP; one translational psychiatry paper examined how ADNP and NAP regulate the excitatory glutamatergic synapse.

Origin and forms

The forms that appear across the verified literature are: (1) endogenous ADNP protein expressed in cells and tissue; (2) the ADNP gene, studied through mutation and knockout models; (3) overexpression constructs used in cell systems, as in work reporting that ADNP exhibited methyltransferase activity in overexpression systems and modulated DNA and histone methylation; and (4) the ADNP-derived NAP fragment used as a laboratory tool alongside the parent protein in synaptic studies. There is no consumer product form described in these papers.

How it has been studied

The methods represented across this reading list include mouse genetics, in one case producing Adnp-mutant mice with cognitive inflexibility, CaMKIIα hyperactivity and synaptic plasticity deficits; cell and tumour biology, including work describing ADNP as a therapeutically inducible repressor of WNT signalling in colorectal cancer; developmental biology showing that ADNP promoted neural differentiation by modulating Wnt/β-catenin signalling; and human clinical description, such as a report on the clinical presentation of a complex neurodevelopmental disorder caused by mutations in ADNP.

Limits of the evidence (Module 1): These papers characterised a protein and a genetic condition. They did not establish ADNP, or any ADNP-derived peptide, as a treatment for anything in humans, and none of them described an ADNP product administered to healthy people.

Module 2: Mechanism as Described in the Literature

Wnt/β-catenin signalling

Two independent lines of work placed ADNP in the Wnt pathway. A 2020 Nature Communications study reported that ADNP promoted neural differentiation by modulating Wnt/β-catenin signalling, framing ADNP as a positive regulator of a differentiation programme. In a different tissue context, a 2017 Clinical Cancer Research paper described ADNP as a therapeutically inducible repressor of WNT signalling in colorectal cancer. Researchers therefore reported context-dependent, not uniform, effects on the same pathway.

Chromatin, methylation and transcription

A 2025 Autism Research paper reported that ADNP exhibited methyltransferase activity in overexpression systems and modulated DNA and histone methylation, which positions ADNP within epigenetic regulation. Consistent with a chromatin-level mechanism, another 2025 study reported that synaptic deficits in Adnp-mutant mice were ameliorated by histone demethylase LSD1 inhibition — an intervention aimed at the histone-modification machinery rather than at ADNP itself.

Synaptic and signalling mechanisms

At the synapse, one study reported that ADNP and the ADNP-derived NAP peptide regulated the excitatory glutamatergic synapse. A 2023 Molecular Psychiatry study reported CaMKIIα hyperactivity together with synaptic plasticity deficits in Adnp-mutant mice, linking loss of ADNP function to a specific downstream kinase signal.

Translation, proteostasis and vascular biology

A 2024 Zoological Research study used integrated ribosome and proteome analyses and reported that sevoflurane-induced long-term social behaviour and cognitive dysfunctions in neonatal mice occurred through ADNP inhibition, implicating translational regulation. Separately, a 2023 oncology paper reported modulatory activity of ADNP on the hypoxia-induced angiogenic process in glioblastoma.

Limits of the evidence (Module 2): Mechanistic claims here came largely from cell systems, overexpression constructs and genetically modified mice. Overexpression findings, as the authors themselves framed them, describe what a protein can do in an engineered system, not necessarily what it does at physiological levels in human tissue. No paper on this list demonstrated that manipulating ADNP mechanism produced a clinical benefit in people.

Module 3: Reported Outcomes by Study

The table below summarises what each study examined and what it reported. It is a reading map, not a comparison of efficacy, and none of these findings should be read as a promise of any outcome.

Limits of the evidence (Module 3): Most outcomes came from animal or cell models, where endpoints are molecular or behavioural proxies. The human papers were descriptive — clinical characterisation and qualitative interviews — not controlled trials with predefined efficacy endpoints. No paper on this list reported that giving ADNP or an ADNP-derived compound to humans changed a clinical outcome.

Module 4: Adnp Side Effects: What Studies Report

Because ADNP is not administered as a marketed drug in the verified literature, the harms described are not drug adverse events. They are, instead, the clinical features associated with ADNP mutation and the deficits reported when ADNP function was reduced experimentally.

Clinical features reported in people with ADNP mutations

A 2019 Biological Psychiatry paper reported that mutations in ADNP caused a complex neurodevelopmental disorder, and a 2018 Autism Research paper reported an autism spectrum phenotype in ADNP syndrome. A 2023 qualitative study reported on the symptoms, therapies and challenges described by families affected by ADNP syndrome, and a 2022 clinical nursing report described the day-to-day experience of living with ADNP syndrome.

Deficits reported when ADNP function was reduced in animals

In mice, researchers reported that Adnp mutation was associated with cognitive inflexibility, CaMKIIα hyperactivity and synaptic plasticity deficits, and a separate 2025 study reported synaptic deficits in Adnp-mutant mice. A 2024 study reported that sevoflurane exposure in neonatal mice produced long-term social behaviour and cognitive dysfunctions through ADNP inhibition, which is a reported harm of reducing ADNP activity rather than of supplying it.

Limits of the evidence (Module 4): None of these papers reported a tolerability profile, an adverse-event table, or a safety dataset for administering ADNP or an ADNP-derived peptide to humans. Absence of reported adverse events in this literature reflects the absence of human administration studies on this list, not a demonstration of safety.

Module 5: Pharmacokinetics Where Data Exist

Pharmacokinetics — absorption, distribution, metabolism, excretion, half-life, bioavailability — describes what a body does to an administered substance. None of the verified papers summarised on this page reported human pharmacokinetic parameters for ADNP or for the ADNP-derived NAP fragment. The 2019 synaptic paper examined how ADNP and NAP regulated the excitatory glutamatergic synapse as a biological question rather than as an exposure-response study, and the 2025 methyltransferase paper worked in overexpression systems, where intracellular protein levels are engineered rather than dosed.

Two structural points explain why this literature is thin. First, ADNP is a large intracellular protein that functions in the nucleus, so the relevant "exposure" question in these studies was gene dosage and protein expression, not plasma concentration. Second, in the mouse studies listed here, researchers manipulated the gene — as in Adnp-mutant mice — rather than infusing a protein, so no clearance or half-life endpoint applied.

Limits of the evidence (Module 5): No dose, no dosing interval, no route of administration and no bioavailability figure for ADNP appears anywhere in the verified papers cited on this page, and none is stated here. Any figure encountered elsewhere should be traced back to a primary source before being trusted.

Module 6: Regulatory Status, Stated Factually

Approved products

ADNP is a human gene and protein, not an approved medicine. There is no FDA-approved drug product whose active ingredient is ADNP, and no approved therapy for ADNP syndrome is described in the verified papers on this list; the clinical literature cited here is descriptive, covering clinical presentation of the disorder caused by ADNP mutations and families' accounts of symptoms, therapies and challenges.

Research-use-only materials

Recombinant ADNP protein, ADNP antibodies, plasmids and related reagents are supplied to laboratories as research-use-only (RUO) materials. RUO labelling means a material is intended for laboratory investigation and is not authorised for diagnostic or therapeutic use in humans; RUO status is a distribution category, not a safety or efficacy assessment.

Compounding

In the United States, pharmacy compounding under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act applies to drug substances that meet defined eligibility criteria, such as being the subject of an applicable USP monograph, a component of an approved drug, or appearing on the relevant FDA bulks lists. ADNP is not an approved drug ingredient, and the verified literature here does not describe it as a compounded preparation. Regulatory categories also differ by country. This is general regulatory information, not legal advice.

Limits of the evidence (Module 6): Regulatory status describes what agencies permit, not what science has shown. A protein can be extensively studied, as ADNP has been in developmental and oncology settings, while remaining entirely outside the approved-product framework.

What the Studies Did Not Test

• Human administration. No verified paper here administered ADNP to human participants or reported a dose, schedule or route.
• Healthy-population effects. The mouse work described deficits arising from Adnp mutation; it did not test whether increasing ADNP in a healthy organism changed anything.
• Long-term safety. No paper on this list reported a longitudinal safety follow-up of an ADNP-based intervention.
• Cross-context generalisation. ADNP was reported to promote a Wnt-dependent differentiation programme in one setting (2020) and to repress WNT signalling in colorectal cancer in another (2017), so findings from one tissue were not shown to transfer to another.
• Translation of rescue experiments. The report that LSD1 inhibition ameliorated synaptic deficits in Adnp-mutant mice was a mouse pharmacology result; it was not a clinical trial and did not establish clinical benefit.
• Comparative endpoints. No head-to-head comparison against an active comparator, and no standardised human outcome measure, appeared in this set of papers.

Read this way, ADNP is best understood as an active area of basic and clinical-genetics research: a chromatin-associated protein with reported roles in DNA and histone methylation and excitatory synapse regulation, and the gene behind a described neurodevelopmental syndrome with an autism spectrum phenotype. Questions about individual health circumstances belong with a licensed clinician.

References

• Integrated ribosome and proteome analyses reveal insights into sevoflurane-induced long-term social behavior and cognitive dysfunctions through ADNP inhibition in neonatal mice (Zoological Research, 2024)
• ADNP Exhibits Methyltransferase Activity in Overexpression Systems and Modulates DNA and Histone Methylation (Autism Research, 2025)
• All in the Family: Living With ADNP Syndrome (Clinical Nurse Specialist, 2022)
• ADNP Syndrome: A Qualitative Assessment of Symptoms, Therapies, and Challenges (Children, 2023)
• ADNP promotes neural differentiation by modulating Wnt/β-catenin signaling (Nature Communications, 2020)
• Adnp-mutant mice with cognitive inflexibility, CaMKIIα hyperactivity, and synaptic plasticity deficits (Molecular Psychiatry, 2023)
• Clinical Presentation of a Complex Neurodevelopmental Disorder Caused by Mutations in ADNP (Biological Psychiatry, 2019)
• ADNP Is a Therapeutically Inducible Repressor of WNT Signaling in Colorectal Cancer (Clinical Cancer Research, 2017)
• The autism/neuroprotection-linked ADNP/NAP regulate the excitatory glutamatergic synapse (Translational Psychiatry, 2019)
• Synaptic Deficits in Adnp-Mutant Mice Are Ameliorated by Histone Demethylase LSD1 Inhibition (Autism Research, 2025)
• The autism spectrum phenotype in ADNP syndrome (Autism Research, 2018)
• Modulatory activity of ADNP on the hypoxia-induced angiogenic process in glioblastoma (International Journal of Oncology, 2023)